Yin, Jiale, Author at MediaMedic

Efficacy and Safety of Crovalimab in Complement Inhibitor-Naive Patients with PNH

By Yin, Jiale 2024.02.20

In September 2023, a study led by Professor Rong Fu from Tianjin Medical University General Hospital was published in the prestigious international academic journal —— American Journal of Hematology(IF=13.268). The title of the…

Immunogenic Cell Death in Hematological Malignancy Therapy

By Yin, Jiale 2024.02.20

In May 2023, a study led by Professor Rong Fu from Tianjin Medical University General Hospital was published in the prestigious international academic journal —— Adv Sci (Weinh) (IF=17.521). The title of the study…

Gene Therapy Using BCMA/CD3 Bispecific Antibody-Encoding Plasmid DNA: A Novel Approach for Treating Multiple Myeloma

By Yin, Jiale 2024.02.20

In May 2023, a study led by Professor Rong Fu from Tianjin Medical University General Hospital was published in the prestigious international academic journal —— British Journal of Haematology(IF=8.615). The title of the…

BSA-AIE Nanoparticles for Immunogenic Cell Death Immunotherapy of Multiple Myeloma

By Yin, Jiale 2024.02.20

In February 2023, a study led by Professor Rong Fu from Tianjin Medical University General Hospital was published in the prestigious international academic journal —— Advanced Materials(IF=32.086). The title of the study is…

Unveiling the Role of BMSCs in NK Cell Exhaustion via the Tim-3/Galectin-9 Pathway in Multiple Myeloma

By Yin, Jiale 2024.02.20

In March 2023, a study led by Professor Rong Fu from Tianjin Medical University General Hospital was published in the prestigious international academic journal —— Clinical And Translational Medicine(IF=10.6). The title of the study…

Polatuzumab Vedotin Enhances Treatment Efficacy in Previously Untreated DLBCL: Insights from the Asia Subpopulation of the POLARIX Trial

By Yin, Jiale 2024.02.07

In April 2023, a study led by Professor Jun Zhu from Peking University Cancer Hospital and Institute was published in the prestigious international academic journal ——Blood (IF=25.669). The title of the study is "Polatuzumab…

$Comprehensive Analysis of Orelabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma: A Phase 1/2 Study$

Comprehensive Analysis of Orelabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma: A Phase 1/2 Study

By Yin, Jiale 2024.02.07

In August 2023, a study led by Professor Jun Zhu from Peking University Cancer Hospital and Institute was published in the prestigious international academic journal ——Blood Advances (IF=7.642). The title of the study is "Orelabrutinib for…

$Orelabrutinib for the Treatment of Relapsed or Refractory Marginal Zone Lymphoma: A Phase 2 Study$

Orelabrutinib for the Treatment of Relapsed or Refractory Marginal Zone Lymphoma: A Phase 2 Study

By Yin, Jiale 2024.02.07

In November 2023, a study led by Professor Jun Zhu from Peking University Cancer Hospital and Institute was published in the prestigious international academic journal ——American Journal of Hematology (IF=12.8). The title of…

$Long-term Survival Benefit of Anti-PD-1 Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma$

Long-term Survival Benefit of Anti-PD-1 Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

By Yin, Jiale 2024.02.07

In September 2023, a study led by Professor Jun Zhu from Peking University Cancer Hospital and Institute was published in the prestigious international academic journal ——Signal Transduction and Targeted Therapy (IF=38.12). The title…

Unlocking the Cure: A Groundbreaking Study on ENKTCL Treatment Success Rates and Implications

By Yin, Jiale 2024.02.07

In September 2023, a retrospective multicentric study led by Professor Jun Zhu from Peking University Cancer Hospital and Institute was published in the prestigious international academic journal ——Haematologica (IF=11.047). The title of the study…